Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

Do TNF inhibitors influence lymphoma development?

Nature Reviews Rheumatology volume 13, pages 697–698 (2017)Cite this article

Subjects

TNF inhibition is associated with an increased risk of lymphoma development. But is this association due to the TNF inhibitors themselves or the patient's underlying disease?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Her, M. & Kavanaugh, A. Advances in use of immunomodulatory agents — a rheumatology perspective. Nat. Rev. Gastroenterol. Hepatol. 12, 363–368 (2015).

    Article  CAS  Google Scholar 

  2. Kalliolias, G. D. & Ivashkiv, L. B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12, 49–62 (2016).

    Article  CAS  Google Scholar 

  3. Dixon, W. G. et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res. (Hoboken) 62, 755–763 (2010).

    Article  CAS  Google Scholar 

  4. Baecklund, E. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692–671 (2006).

    Article  Google Scholar 

  5. Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1–26 (2016).

    PubMed  Google Scholar 

  6. Mercer, L. K. et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann. Rheum. Dis. 76, 497–503 (2017).

    Article  Google Scholar 

  7. Mercer, L. K. et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211623 (2017).

Download references

Acknowledgements

The research of A.K is supported in part by the Phil and Amy Mickelson Charitable Foundation

Author information

Authors and Affiliations

  1. Arthur Kavanaugh is at the Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, California 92093–0943, USA.,

    Arthur Kavanaugh

Authors
  1. Arthur Kavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arthur Kavanaugh.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kavanaugh, A. Do TNF inhibitors influence lymphoma development?. Nat Rev Rheumatol 13, 697–698 (2017). https://doi.org/10.1038/nrrheum.2017.186

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.186

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing